Orthocell (ASX:OCC) appoints leading US surgeons to advisory board

Australian regenerative medicine firm Orthocell (ASX:OCC) has appointed internationally recognised orthopaedic surgeons, Professor Christopher Dy and Professor David Brogan onto its Medical Scientific Advisory Board.

The Professors, based at the Washington University and Barnes-Jewish Orthopedic Center, have been appointed to assist with clinical development and US market access for Orthocell’s nerve repair medical device.

Orthocell says both surgeons bring a wealth of clinical and research expertise, including significant experience advancing pre-clinical and clinical research programs.

It also says with these additions to the specialist advisory team, the company is ideally positioned to drive its device into the US market.